At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety of Reduced Methotrexate Lab Monitoring: a Population-based, Target Trial Emulation Study
In Brief
An observational study evaluating Standard methotrexate lab monitoring and Reduced methotrexate lab monitoring for Rheumatic Diseases. Completed, enrolled 2,414 participants.
Detailed Summary
The goal of this retrospective, observational study is to learn more about the risks and benefits of methotrexate lab monitoring. The main question it aims to answer is: \- Is reduced methotrexate lab monitoring non-inferiorly safe when compared to standard lab monitoring? Differences in end-organ damage and/or death will be compared between participants who have previously been treated with methotrexate for various rheumatic diseases and have undergone varying intervals of methotrexate lab monitoring
Study Details
Timeline
Interventions
This group will undergo standard or guidelines based frequency of methotrexate lab monitoring, defined as lab monitoring 3+ times in first 0-3 months, 3+ times in 3 to 12 months, and at least once every 4.5 months afterward.
This group will undergo reduced frequency of methotrexate lab monitoring, defined as lab monitoring 1-2 times in first 0-3 months, 1-2 times in 3 to 12 months, and at least once per year afterward (but not more than once every 4.5 months).